{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:36Z","timestamp":1792784616954,"version":"4.5.0"},"reference-count":39,"publisher":"American Chemical Society (ACS)","issue":"19","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZB20250222"],"award-info":[{"award-number":["GZB20250222"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Municipal Natural Science Foundation","award":["2264089"],"award-info":[{"award-number":["2264089"]}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["22022601"],"award-info":[{"award-number":["22022601"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["22376016"],"award-info":[{"award-number":["22376016"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Carbonic Anhydrase IX (CAIX) is an attractive biomarker for clear cell renal cell carcinoma (ccRCC), but small-molecule CAIX radiotracers are often limited by insufficient tumor retention and suboptimal tumor-to-kidney contrast. Herein, we report the rational design of biphenyl-containing bivalent sulfonamide tracers and evaluation of both 68Ga and Al18F-labeled analogues. Guided by a multivalency strategy, [68Ga]Ga-CAIX-D1 and [68Ga]Ga-CAIX-N1 were developed and compared with the monomeric reference tracer [68Ga]Ga-14. In OS-RC-2 xenografts, both dimers showed higher tumor uptake, improved tumor retention, and tumor-to-kidney ratios greater than 1. The lead scaffold was further adapted to generate [18F]AlF-CAIX-N1, which displayed high tumor uptake, excellent tumor-to-muscle contrast, CAIX-specific uptake, and lower liver uptake than its 68Ga-labeled counterpart. First-in-human positron emission tomography\/computed tomography (PET\/CT) imaging further supported its translational feasibility. Collectively, [18F]AlF-CAIX-N1 is a promising tracer for ccRCC imaging and highlights the value of integrating bivalency with radiolabel engineering.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01183","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:03:48Z","timestamp":1790355828000},"page":"22088-22101","source":"Crossref","is-referenced-by-count":0,"title":["A Biphenyl-Containing Dimeric Sulfonamide PET Tracer for High-Contrast Imaging of Carbonic Anhydrase IX in Clear Cell Renal Cell Carcinoma"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1602-3253","authenticated-orcid":true,"given":"Yimin","family":"Chen","sequence":"first","affiliation":[{"name":"Beijing Normal University , , ,","place":["Beijing, China, 100875"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjia","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Normal University , , ,","place":["Beijing, China, 100875"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Li","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Qingdao University , , ,","place":["Qingdao, China, 266061"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Qingdao University , , ,","place":["Qingdao, China, 266061"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Yang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Qingdao University , , ,","place":["Qingdao, China, 266061"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-7864","authenticated-orcid":true,"given":"Mengchao","family":"Cui","sequence":"additional","affiliation":[{"name":"Beijing Normal University , , ,","place":["Beijing, China, 100875"]},{"name":"Beijing Normal University , , ,","place":["Zhuhai, China, 519087"]},{"name":"Beijing Normal University , , ,","place":["Beijing, China, 100875"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"12","key":"2026100811110594700_cit1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal Cell Carcinoma: A Review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"2026100811110594700_cit2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.urolonc.2011.10.005","article-title":"Consolidative Surgery after Targeted Therapy for Renal Cell Carcinoma","volume":"31","author":"Thomas","year":"2013","journal-title":"Urol. Oncol."},{"issue":"1","key":"2026100811110594700_cit3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/cancers14010239","article-title":"Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therap","volume":"14","author":"Mattila","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"2026100811110594700_cit4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59956","article-title":"Multifaceted Imaging of Renal Lesions with an Emphasis on Cross-Sectional Imaging","volume":"16","author":"Dev","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"2026100811110594700_cit5","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1097\/01.ju.0000095475.12515.5e","article-title":"Solid Renal Tumors: an Analysis of Pathological Features Related to Tumor Size","volume":"170","author":"Frank","year":"2003","journal-title":"J. Urol."},{"issue":"1","key":"2026100811110594700_cit6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF Axis in Clear Cell Renal Carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin. Cancer Biol."},{"issue":"1\u22122","key":"2026100811110594700_cit7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","article-title":"The Role of Carbonic Anhydrase IX in Cancer Development: Links to Hypoxia, Acidosis, and Beyond","volume":"38","author":"Pastorekova","year":"2019","journal-title":"Cancer Metastasis Rev."},{"issue":"19","key":"2026100811110594700_cit8","doi-asserted-by":"publisher","first-page":"7146","DOI":"10.3390\/ijms21197146","article-title":"Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management","volume":"21","author":"Courcier","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2026100811110594700_cit9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fonc.2016.00201","article-title":"The Place of FDG PET\/CT in Renal Cell Carcinoma: Value and Limitations","volume":"6","author":"Liu","year":"2016","journal-title":"Front. Oncol."},{"issue":"10","key":"2026100811110594700_cit10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/s1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET-CT Imaging of Clear-Cell Renal Cell Carcinoma: a Prospective, Open-Label, Multicentre, Phase 3 Trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026100811110594700_cit11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/jco.2011.41.2445","article-title":"Positron Emission Tomography\/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results from the REDECT Trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"2026100811110594700_cit12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/s1470-2045(07)70044-x","article-title":"Preoperative Characterisation of Clear-Cell Renal Carcinoma Using Iodine-124-Labelled Antibody Chimeric G250 (124I-cG250) and PET in patients with Renal Masses: a Phase I Trial","volume":"8","author":"Divgi","year":"2007","journal-title":"Lancet Oncol."},{"issue":"8","key":"2026100811110594700_cit13","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1016\/j.apsb.2025.05.030","article-title":"Advances in ImmunoPET\/SPECT Imaging: The Role of Fab and F(ab\u2019)2 Fragments in Theranostics","volume":"15","author":"Huang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"2026100811110594700_cit14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2967\/jnumed.109.073189","article-title":"PET of Hypoxia with 89Zr-Labeled cG250-F(ab\u2019)2 in Head and Neck Tumors","volume":"51","author":"Hoeben","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026100811110594700_cit15","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1038\/s41598-019-51445-w","article-title":"Comparative Evaluation of Affibody- and Antibody Fragments-Based CAIX Imaging Probes in Mice Bearing Renal Cell Carcinoma Xenografts","volume":"9","author":"Garousi","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"2026100811110594700_cit16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"6_Supplement","key":"2026100811110594700_cit17","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1158\/1538-7445.am2024-6024","article-title":"Abstract 6024: A Novel Carbonic Anhydrase IX Targeting Radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, Exhibit Promising Theranostic Potential in ccRCC Tumors","volume":"84","author":"Mizukoshi","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"2026100811110594700_cit18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/cbr.2014.1741","article-title":"Peptide Receptor Radionuclide Therapy: an Overview","volume":"30","author":"Dash","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"issue":"6","key":"2026100811110594700_cit19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2967\/jnumed.115.170514","article-title":"A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo","volume":"57","author":"Krall","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"13","key":"2026100811110594700_cit20","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1007\/s00259-024-06801-y","article-title":"Diagnostic Efficacy of [68Ga]Ga-NY104 PET\/CT to Identify Clear Cell Renal Cell Carcinoma","volume":"51","author":"Zhu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026100811110594700_cit21","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s00259-024-07007-y","article-title":"Evaluation of the Safety, Biodistribution, Dosimetry of [18F]AlF-NYM005 and Initial Experience in Clear Cell Renal Cell Carcinoma: an Interim Analysis of a Prospective Trial","volume":"52","author":"Yang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"2026100811110594700_cit22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.2967\/jnumed.114.153288","article-title":"Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IX-Targeted PET Imaging","volume":"56","author":"Lau","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026100811110594700_cit23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243327","article-title":"PET Imaging and Pharmacological Therapy Targeting Carbonic Anhydrase-IX high-expressing tumors using US2 platform based on Bivalent Ureidosulfonamide","volume":"15","author":"Iikuni","year":"2020","journal-title":"PLoS One"},{"key":"2026100811110594700_cit24","doi-asserted-by":"publisher","first-page":"112923","DOI":"10.1016\/j.ejmech.2020.112923","article-title":"Recent advances in the medicinal chemistry of Carbonic Anhydrase Inhibitors","volume":"209","author":"Kumar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"2026100811110594700_cit25","doi-asserted-by":"publisher","first-page":"13332","DOI":"10.1021\/acs.jmedchem.3c01475","article-title":"Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [68Ga]-Labeled Biphenyl-Containing PSMA Tracers","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026100811110594700_cit26","doi-asserted-by":"publisher","first-page":"118577","DOI":"10.1016\/j.ejmech.2026.118577","article-title":"Preclinical Evaluation of 68Ga-Labeled Acetazolamide Derivatives as Radiotracers Targeting Carbonic Anhydrase IX in Clear Cell Renal Cell Carcinoma","volume":"305","author":"Liu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"2026100811110594700_cit27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/cancers18020195","article-title":"Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications","volume":"18","author":"Al-Khanaty","year":"2026","journal-title":"Cancers"},{"issue":"1","key":"2026100811110594700_cit28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.62347\/VHYY2134","article-title":"CAIX-Targeted PET Imaging Agents Based on Acetazolamide Small Molecule for Clear Cell Renal Cell Carcinoma","volume":"15","author":"Li","year":"2025","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026100811110594700_cit29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/ol.2026.15505","article-title":"Application of Carbonic Anhydrase IX-Targeted Radiopharmaceuticals in the Diagnosis and Treatment of Clear Cell Renal Cell Carcinoma (Review)","volume":"31","author":"Wang","year":"2026","journal-title":"Oncol. Lett."},{"issue":"6","key":"2026100811110594700_cit30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41585-024-00962-z","article-title":"Molecular imaging of Renal Cell Carcinomas: Ready for Prime Time","volume":"22","author":"Wu","year":"2025","journal-title":"Nat. Rev. Urol."},{"issue":"9","key":"2026100811110594700_cit31","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026100811110594700_cit32","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2967\/jnumed.125.270069","article-title":"Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer","volume":"66","author":"Chen","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026100811110594700_cit33","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1021\/bc200197h","article-title":"Comparison Study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET Imaging of U87MG Tumors in Mice","volume":"22","author":"Lang","year":"2011","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"2026100811110594700_cit34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/c3cs60304k","article-title":"Matching Chelators to Radiometals for Radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"issue":"7","key":"2026100811110594700_cit35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"key":"2026100811110594700_cit36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.nucmedbio.2018.05.002","article-title":"Brush Border Enzyme-Cleavable Linkers: Evaluation for Reducing Renal Uptake of Radiolabeled Prostate-Specific Membrane Antigen Inhibitors","volume":"62\u221263","author":"Vaidyanathan","year":"2018","journal-title":"Nucl. Med. Biol."},{"issue":"17","key":"2026100811110594700_cit37","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.3390\/molecules25173854","article-title":"Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics","volume":"25","author":"Bendre","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"2026100811110594700_cit38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1021\/bc300428b","article-title":"Renal Brush Border Enzyme-Cleavable Linkages for Low Renal Radioactivity Levels of Radiolabeled Antibody Fragments","volume":"24","author":"Akizawa","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"2026100811110594700_cit39","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s00259-021-05486-x","article-title":"68Ga-Labeled ODAP-Urea-Based PSMA Agents in Prostate Cancer: First-in-Human Imaging of an Optimized Agent","volume":"49","author":"Duan","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01183","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22088\/68661736\/jm6c01183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22088\/68661736\/jm6c01183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:24:55Z","timestamp":1791473095000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/19\/22088\/5439047\/A-Biphenyl-Containing-Dimeric-Sulfonamide-PET"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":39,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01183","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}